Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Average Rating of “Reduce” from Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has received an average recommendation of “Reduce” from the seven analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating and four have issued a hold rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $28.00.

A number of equities research analysts recently commented on FMS shares. Bank of America cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Weiss Ratings lowered Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. Finally, Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE FMS opened at $21.68 on Friday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.94 and a 1-year high of $30.46. The business has a fifty day moving average price of $23.29 and a 200 day moving average price of $24.93. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its earnings results on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. The business had revenue of $5.73 billion during the quarter, compared to the consensus estimate of $4.72 billion. Research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of institutional investors have recently bought and sold shares of FMS. TD Waterhouse Canada Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at approximately $36,000. CIBC Private Wealth Group LLC grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after buying an additional 1,103 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at $43,000. Hantz Financial Services Inc. raised its stake in Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after acquiring an additional 1,768 shares during the last quarter. Finally, Huntington National Bank lifted its position in Fresenius Medical Care AG & Co. KGaA by 219.5% during the 2nd quarter. Huntington National Bank now owns 2,355 shares of the company’s stock worth $67,000 after acquiring an additional 1,618 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.